Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia.

Nature communications - 21 Nov 2023

Lorentzian Amanda C, Rever Jenna, Ergin Enes K, Guo Meiyun, Akella Neha M, Rolf Nina, James Lim C, Reid Gregor S D, Maxwell Christopher A, Lange Philipp F

Abstract excerpt

Childhood acute lymphoblastic leukemia (ALL) genomes show that relapses often arise from subclonal outgrowths. However, the impact of clonal evolution on the actionable proteome and response to targeted therapy is not known. Here, we present a comprehensive retrospective analysis of paired ALL diagnosis and relapsed specimen. Targeted next generation sequencing and proteome analysis indicate persistence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to PARP inhibition in cancer therapy

Share to Precision Medicine

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Proteome

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 37989729
DOI: 10.1038/s41467-023-42701-9
PMCID: PMC10663560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia.PMID 37989729Read ↗

Persistence of targetable lesions, predicted therapy sensitivity and proteomes through disease evolution in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

Multi-omics molecular phenotyping of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilitiesSemantic proximity Read ↗

Single-Cell Sequencing Reveals Extensive Genetic Diversity Underlying Pediatric ALL Treatment ComplexitySemantic proximity Read ↗

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell linesSemantic proximity Read ↗

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.Semantic proximity Read ↗

Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.Semantic proximity Read ↗

Addressing the Global Diagnostics Gap for Childhood Leukemias: A Global, Multisite Type 2 Hybrid Validation Study of Nanopore-based Adaptive Sampling Whole Genome SequencingSemantic proximity Read ↗

PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathwaysSemantic proximity Read ↗

Role of Stem-Like Cells in Chemotherapy Resistance and Relapse in pediatric T Cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathwaysSemantic proximity Read ↗

Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.